Authors
Constança Britto, Otacilio da Cruz Moreira
Published in
Memorias do Instituto Oswaldo Cruz. Volume 121. Issue suppl 2. Pages e260186. Epub Nov 16, 2026.
Abstract
An estimated 6 to 8 million people worldwide are infected with Trypanosoma cruzi, the parasite that causes Chagas disease (CD). Of those infected, an alarming 70% to 90% remain undiagnosed, making it one of the most under-recognised global health burdens. To celebrate the 25th anniversary of the Fiocruz Translational Programme in Chagas Disease (Fio-Chagas), this narrative review presents a chronological account of the development of polymerase chain reaction (PCR)-based assays for the molecular detection of T. cruzi. It highlights the significant contributions made by the Fio-Chagas Programme to the development and availability of a diagnostic product for the molecular diagnosis of CD. Following the proof of concept, the qPCR-based Biomol Chagas kit was manufactured using reagents produced by the Institute of Molecular Biology of Paraná (IBMP). After analytical and clinical validation, the kit was registered in 2022 by the Brazilian Health Regulatory Agency (ANVISA). Additional studies under field conditions were required for a cost-effectiveness analysis by the National Commission for the Incorporation of Technologies into the Brazilian Unified Health System (CONITEC). Currently, the kit has been incorporated into clinical studies across Latin America to diagnose congenital transmission, monitor the impact of antiparasitic treatment in chronic CD (CCD), and evaluate oral transmission in the Northern region of Brazil.
PMID:
43049019
Bibliographic data and abstract were imported from PubMed on 18 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 4
- Comments 0